NASDAQ: LBRXLb Pharmaceuticals Inc Stock
$16.80-0.50 (-2.89%)
Updated Sep 12, 2025
LBRX Price
$16.80
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$15.79
52 Week High
$20.25
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.09
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LBRX Overview
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LBRX's potential to beat the market
- LBRX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LBRX
RankedUnranked of 476
RankedUnranked of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.30 | A | |
| $37.96 | A | |
| $7.91 | A |
Be the first to know about important LBRX news, forecast changes, insider trades & much more!
LBRX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LBRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LBRX's short-term assets ($14.78M) exceed its short-term liabilities ($3.91M)
Short-term Liabilities Financials
LBRX's short-term assets ($14.78M) exceed its long-term liabilities ($4.96M)
Long-term Liabilities Financials
LBRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more LBRX due diligence checks available for Premium users.
Valuation
LBRX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$19.2M
Liabilities
$8.9M
Debt to equity
-0.09
LBRX's short-term assets ($14.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LBRX's short-term assets ($14.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LBRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LBRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Lb Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.